Taysha Gene Therapies prices $200M public offering of 32.5M shares at $6.00/share

Taysha Gene Therapies, Inc.

Offering of 32,500,001 shares at $6.00/share and 833,333 pre-funded warrants at $5.999.
Net proceeds ~$187.4M; up to ~$215.6M if underwriters exercise 5M over-allotment option.
Underwriters: Jefferies, Goldman Sachs, Piper Sandler, Cantor; Baird as lead manager.
Company expects cash runway into second half of 2028.
Offering expected to close June 26, 2026; dilution to existing shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.